Literature DB >> 2786876

mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DR beta 1 and -DR beta 3 molecules.

T Cotner1, H Charbonneau, E Mellins, D Pious.   

Abstract

The class II major histocompatibility molecules HLA-DR are formed by the association of a single DR alpha chain with two nonallelic DR beta chains. In DR3 cells one DR beta chain is severalfold more abundant than the other. We have studied the mechanism that controls the differential expression of these DR beta genes. We determined the amino-terminal sequences of the two expressed DR beta chains. Comparison of these sequences with the nucleotide sequences of the DR3B1 and DRB3a genes indicates that the abundant chain is the B1 gene product. Supporting this conclusion, an informative mutant, 9.4.3, was found to have lost the abundant beta chain and beta 1 mRNA. This mutant expresses normal cell surface levels of the DR beta 3 chain and exhibits no significant dosage compensation of its beta 3 chain. The unchanged level of DR beta 3 dimer on the cell surface suggests that free DR alpha chains are not the limiting factor in the surface expression of the beta 3 chain and, further, that the differential regulation of the surface expression of the two DR beta chains occurs at a step prior to DR assembly. Quantitation of DR beta mRNAs by locus-specific oligonucleotide probes showed that beta 1 mRNA is 4.5-fold more abundant than beta 3 mRNA, strongly indicating that the greater surface expression of DR beta 1 is a direct consequence of greater beta 1 mRNA abundance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786876

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Point mutations define positions in HLA-DR3 molecules that affect antigen presentation.

Authors:  E Mellins; B Arp; D Singh; B Carreno; L Smith; A H Johnson; D Pious
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

2.  Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Authors:  Maha Ayyoub; Danijel Dojcinovic; Pascale Pignon; Isabelle Raimbaud; Julien Schmidt; Immanuel Luescher; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

3.  Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis.

Authors:  Johannes R Hov; Vasilis Kosmoliaptsis; James A Traherne; Marita Olsson; Kirsten M Boberg; Annika Bergquist; Erik Schrumpf; J Andrew Bradley; Craig J Taylor; Benedicte A Lie; John Trowsdale; Tom H Karlsen
Journal:  Hepatology       Date:  2011-05-13       Impact factor: 17.425

4.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

5.  Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.

Authors:  S P Fling; J Rak; K A Muczynski; B Arp; D Pious
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

6.  Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Authors:  Kwangwoo Kim; So-Young Bang; Dae Hyun Yoo; Soo-Kyung Cho; Chan-Bum Choi; Yoon-Kyoung Sung; Tae-Hwan Kim; Jae-Bum Jun; Young Mo Kang; Chang-Hee Suh; Seung-Cheol Shim; Shin-Seok Lee; Jisoo Lee; Won Tae Chung; Seong-Kyu Kim; Jung-Yoon Choe; Swapan K Nath; Hye-Soon Lee; Sang-Cheol Bae
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

7.  The prevalence of antibodies against the HLA-DRB3 protein in kidney transplantation and the correlation with HLA expression.

Authors:  Thomas H P M Habets; Bouke G Hepkema; Niels Kouprie; Melanie C A Schnijderberg; Tim C van Smaalen; Laura B Bungener; Maarten H L Christiaans; Gerard M J Bos; Joris Vanderlocht
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.